The Impact of "First-Line" Rhythm Therapy on AF Progression
Status:
Active, not recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The PROGRESSIVE-AF Trial is a national, multi-center randomized controlled trial comparing
early ("first-line") catheter-based pulmonary vein isolation (PVI) using cryothermal energy
to first-line anti-arrhythmic drug therapy. The aim of the trial is to evaluate if the
initial treatment choice (ablation vs. pharmacotherapy) influences AF disease progression, as
measured by continuous cardiac monitoring. The outcomes of interest are disease progression,
quality of life, and healthcare utilisation. The targeted population consists of healthy
patients with symptomatic paroxysmal AF without clinically significant heart diseases aged
between 18 and 75 years. This study represents a new research project leveraging the existing
EARLY-AF randomised clinical trial infrastructure to examine the novel endpoints of: 1)
disease progression ("time to first episode of persistent AF"), 2) progressive AF burden ("%
time in AF"), 3) Quality of Life, and 4) healthcare utilisation at 36 months of follow-up.
Phase:
N/A
Details
Lead Sponsor:
University of British Columbia
Collaborators:
Medtronic Ottawa Heart Institute Research Corporation